Biglycan, a Nitric Oxide-regulated Gene, Affects Adhesion, Growth, and Survival of Mesangial Cells

Liliana Schaefer, Karl-Friedrich Beck, Igor Raslik, Sebastian Walpen, Daniel Mihalik, Miroslava Micegova, Katarina Macakova, Elke Schönherr, Daniela G. Seidler, Georg Varga, Roland M. Schaefer, Hans Kresse (+1 others)
2003 Journal of Biological Chemistry  
During glomerular inflammation mesangial cells are the major source and target of nitric oxide that profoundly influences proliferation, adhesion, and death of mesangial cells. The effect of nitric oxide on the mRNA expression pattern of cultured rat mesangial cells was therefore investigated by RNA-arbitrarily-primed polymerase chain reaction. Employing this approach, biglycan expression turned out to be down-regulated timeand dose-dependently either by interleukin-1␤-stimulated endogenous
more » ... ic oxide production or by direct application of the exogenous nitric oxide donor, diethylenetriamine nitric oxide. There was a corresponding decline in the rate of biglycan biosynthesis and in the steady state level of this proteoglycan. In vivo, in a model of mesangioproliferative glomerulonephritis upregulation of inducible nitric-oxide synthase mRNA was associated with reduced expression of biglycan in isolated glomeruli. Biglycan expression could be normalized, both in vitro and in vivo, by using a specific inhibitor of the inducible nitric-oxide synthase, l-N 6 -(l-iminoethyl)-l-lysine dihydrochloride. Further studies showed that biglycan inhibited cell adhesion on type I collagen and fibronectin because of its binding to these substrates. More importantly, biglycan protected mesangial cells from apoptosis by decreasing caspase-3 activity, and it counteracted the proliferative effects of platelet-derived growth factor-BB. These findings indicate a signaling role of biglycan and describe a novel pathomechanism by which nitric oxide modulates the course of renal glomerular disease through regulation of biglycan expression. * This work was supported by the Deutsche Forschungsgemeinschaft (SFB 492, project B10 and SFB 553, projects SCHA 970/1-1 and PF 361/1-1) and the Interdisciplinary Centre for Clinical Research, University of Mü nster (Project D18).
doi:10.1074/jbc.m210574200 pmid:12719420 fatcat:e3qjcnlayrcmtchmuvbvvdxyiu